Accelerated Approval
A drug granted Accelerated Approval is approved based on evidence of impact on a surrogate endpoint rather than evidence of impact on the actual clinical benefit the drug is intended to provide.
Priority review
The drug must demonstrate, through clinical trial data or other scientifically valid information, the potential to provide a significant improvement in safety or effectiveness over existing treatments.
For mine it’s just a matter of which one comes next , accelerated approval or priority review?
DYOR
Media, page-555
-
- There are more pages in this discussion • 189 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |